Synthetic Microchromosome vector delivery systems
Latest Information Update: 20 Mar 2007
At a glance
- Originator Athersys
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Unspecified
Most Recent Events
- 20 Mar 2007 Discontinued - Preclinical for Undefined in USA (Parenteral)
- 02 Jul 2002 This technology is still in active development
- 12 Apr 2000 Preclinical development for Undefined in USA (Parenteral)